drugset

drugset / Trial / NCT00376324

Study Evaluating the Pharmacokinetics of Tigecycline in Human Bone

NCT00376324 ↗

Phase 1 Completed 36 enrolled Wyeth is now a wholly owned subsidiary of Pfizer

Non-randomizedSingle-groupOpen-labelTreatment

Summary

Study to examine the concentration of the study drug, tigecycline, in human bone samples following the administration of multiple doses.

Timeline

Start: 2006-09
Primary completion: 2008-10
Completion: 2008-10

Publications

Bhattacharya I, Gotfried MH, Ji AJ, Saunders JP, Gourley I, Diehl A, Korth-Bradley JM. Reassessment of tigecycline bone concentrations in volunteers undergoing elective orthopedic procedures. J Clin Pharmacol. 2014 Jan;54(1):70-4. doi: 10.1002/jcph.201. Epub 2013 Oct 24.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Tigecycline	Small molecule	50 mg	Intravenous

Indications

No indication recorded.